Drug Type Small molecule drug |
Synonyms 斯美瑞非, TPN-171-H, TPN171 + [3] |
Target |
Action inhibitors |
Mechanism PDE5A inhibitors(Phosphodiesterase 5A inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date Uzbekistan (01 Sep 2022), |
Regulation- |
Molecular FormulaC24H36ClN5O3 |
InChIKeyOXNGBNVLPXLUPV-UHFFFAOYSA-N |
CAS Registry2258665-07-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Erectile Dysfunction | Uzbekistan | 01 Sep 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Familial Primary Pulmonary Hypertension | Phase 2 | China | 16 Nov 2020 | |
Familial Primary Pulmonary Hypertension | Phase 2 | China | 16 Nov 2020 | |
Familial Primary Pulmonary Hypertension | Phase 2 | China | 16 Nov 2020 | |
Familial Primary Pulmonary Hypertension | Phase 2 | China | 16 Nov 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 2 | China | 16 Nov 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 2 | China | 16 Nov 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 2 | China | 16 Nov 2020 | |
Idiopathic pulmonary arterial hypertension | Phase 2 | China | 16 Nov 2020 | |
Pulmonary Arterial Hypertension | Phase 2 | China | 16 Nov 2020 | |
Pulmonary Arterial Hypertension | Phase 2 | China | 16 Nov 2020 |